News

Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation recently completed a Phase 2 clinical ...
Discover a study exploring how GLP-1 receptor agonists may reduce symptoms of hidradenitis suppurativa through weight loss and anti-inflammatory effects.
Adults with hidradenitis suppurativa treated with adalimumab have a greater risk for serious infections than those with ...
GLP-1 receptor agonists show promise in treating hidradenitis suppurativa, offering significant symptom relief and improved ...
A multicenter French study led by Rennes University Hospital reports potential benefits of glucagon-like peptide-1 receptor ...
A significant burden of neuropsychiatric comorbidities exists among patients with PPD and various psychophysiological disorders.
Discover Insmed's innovative therapies targeting rare diseases, with approvals like Brinsupri boosting potential.
Discover a study validating a disease-specific quality-of-life tool for hidradenitis suppurativa, confirming its reliability, ...
We came across a bullish thesis on MoonLake Immunotherapeutics on Valueinvestorsclub.com by skimmer610. In this article, we will summarize the bulls’ thesis on MLTX. MoonLake Immunotherapeutics’s ...
Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing hidradenitis suppurativa severity and pain, especially in patients with obesity.
Panelists discuss the critical importance of early biologic therapy initiation in hidradenitis suppurativa to prevent irreversible tissue damage, reduce disease burden, and overcome socioeconomic and ...
The study also noted a 15% drop in substance misuse and showed benefit for patients who were taking stimulant medications rather than nonstimulants. Plus: developing new painkillers; how semaglutide ...